Nilutamide
Nilutamide structure
|
Common Name | Nilutamide | ||
|---|---|---|---|---|
| CAS Number | 63612-50-0 | Molecular Weight | 317.221 | |
| Density | 1.5±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C12H10F3N3O4 | Melting Point | 1490C | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS06, GHS08 |
Signal Word | Danger | |
|
Phase I and phase II reductive metabolism simulation of nitro aromatic xenobiotics with electrochemistry coupled with high resolution mass spectrometry.
Anal. Bioanal. Chem 406(28) , 7253-60, (2014) Electrochemistry combined with (liquid chromatography) high resolution mass spectrometry was used to simulate the general reductive metabolism of three biologically important nitro aromatic molecules: 3-trifluoromethyl-4-nitrophenol (TFM), niclosamide, and ni... |
|
|
Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.
J. Phys. Chem. B 118(33) , 9974-82, (2014) Amorphous forms of drugs are increasingly being used to deliver poorly water-soluble compounds. Therefore, understanding the magnitude and origin of differences in crystallization kinetics is highly important. The goal of this study was to better understand t... |
|
|
High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
Assay Drug Dev. Technol. 12(7) , 395-418, (2014) The androgen receptor-transcriptional intermediary factor 2 (AR-TIF2) positional protein-protein interaction (PPI) biosensor assay described herein combines physiologically relevant cell-based assays with the specificity of binding assays by incorporating str... |
|
|
Fulminant hepatic failure due to nilutamide hepatotoxicity.
Dig. Dis. Sci. 54(4) , 910-3, (2009)
|
|
|
Delayed dark adaptation caused by nilutamide.
J. Neuroophthalmol. 28(2) , 158-9, (2008)
|
|
|
Metabolism of nilutamide in rat lung.
Biochem. Pharmacol. 71(3) , 377-85, (2006) Nilutamide is a non-steroidal anti-androgen drug proposed in the treatment of metastatic prostatic carcinoma. Its therapeutic effects are overshadowed by the occurrence of adverse reactions, mediated by mechanisms that remain elusive. To elucidate possible me... |
|
|
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Clin. Cancer Res. 14(14) , 4526-31, (2008) We reported previously the first randomized study of any kind in patients with nonmetastatic, castrate-resistant prostate cancer. The study employed vaccine, the hormone nilutamide, and the combined therapy (crossover for each arm) with an endpoint of time to... |
|
|
Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Prostate 67(8) , 799-807, (2007) Molecular basis for secondary antiandrogen therapy in prostate cancer with mutant androgen receptors (ARs) is not fully elucidated.Effects of steroidal and non-steroidal antiandrogens on transcriptional activities of wild-type and mutant (W741C, T877A, and W7... |
|
|
Androgenic and antiandrogenic effects and expression of androgen receptor in mouse embryonic stem cells.
Fertil. Steril. 85 Suppl 1 , 1195-203, (2006) To investigate the effects of androgen and antiandrogen and the expression of androgen receptor on mouse embryonic stem cells (ESCs) and the inner cell mass.Controlled laboratory study.Academic university hospital.Blastocysts from mice developed at the Instit... |
|
|
Antiandrogenic activity of pyrethroid pesticides and their metabolite in reporter gene assay.
Chemosphere 66(3) , 474-9, (2007) Many pesticides possess hormonal activity and have thus been classified as endocrine disruptors. Pyrethroids are commonly used pesticides worldwide, but little has been done to characterize their antiandrogenic activity potential. We tested three frequently e... |